Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA). Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology No. 50. 2015 Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Monoclonal /therapeutic use; Antineoplastic Agents /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Clinical Trials, Phase II as Topic; Drug Synergisms; Melanoma /drug therapy /immunology; Neoplasm Metastasis; Skin Neoplasms /drug therapy /immunology /pathology Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 Email: anna.nachtnebel@hta.lbg.ac.at AccessionNumber 32015000944 Date abstract record published 24/08/2015 |